Celgene Corporation (NASDAQ:CELG) received a $162.00 target price from research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, October 16th. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 62.02% from the stock’s previous close.
CELG has been the topic of several other research reports. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price target on the stock. in a report on Tuesday, August 29th. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, September 13th. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and raised their target price for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a report on Tuesday, July 11th. Finally, Barclays PLC raised their price target on Celgene Corporation from $135.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $143.45.
Celgene Corporation (NASDAQ:CELG) traded down 3.05% during trading on Monday, reaching $96.94. 16,916,151 shares of the company were exchanged. Celgene Corporation has a 12 month low of $95.52 and a 12 month high of $147.17. The stock has a 50 day moving average price of $139.20 and a 200 day moving average price of $130.37. The firm has a market capitalization of $75.84 billion, a PE ratio of 30.02 and a beta of 1.88.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.58 earnings per share. On average, analysts expect that Celgene Corporation will post $7.31 EPS for the current fiscal year.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/celgene-corporation-celg-given-a-162-00-price-target-by-cantor-fitzgerald-analysts.html.
In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock worth $6,268,259 in the last 90 days. Company insiders own 0.95% of the company’s stock.
A number of institutional investors have recently bought and sold shares of CELG. Janus Henderson Group PLC boosted its position in Celgene Corporation by 4,290.5% during the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after acquiring an additional 8,217,433 shares in the last quarter. BlackRock Inc. boosted its position in shares of Celgene Corporation by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. bought a new stake in shares of Celgene Corporation in the 2nd quarter worth approximately $271,605,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Celgene Corporation by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Celgene Corporation by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares in the last quarter. 79.23% of the stock is currently owned by institutional investors and hedge funds.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.